Fundz
Free weekly newsletter

Get the free weekly funding digest

The new funding rounds, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New funding rounds, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Industry Trends

See who's moving and how much in your market

No credit card required Weekly funding digest

Halia Therapeutics Announces $30M Series C Financing to Advance Novel Pipeline of Anti-Inflammatory Therapeutics

PRIVATEJan 31, 2024over 2 years ago

Amount Raised

$30 Million

LehiBiotechnology

Investors

Todd Pedersen

Description

Halia Therapeutics announced the completion of a $30 million Series C financing led by Todd Pedersen, with continued participation from existing investors. The funds will support the advancement of lead programs in Phase II clinical trials, evaluating HT-6184, Halia's first-in-class NLRP3/NEK7 inflammasome inhibitor, and advancing additional programs into the clinic.

Company Information

Company

Halia Therapeutics

Location

3900 N. Traverse Mountain Blvd

Lehi, Utah, United States

About

Halia is a clinical-stage biopharmaceutical company discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.

Related People

Suggested for you
1 contact

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Halia Therapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.

Watching Halia Therapeutics? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demoChoose your plan